Aeras & OETC Start Tuberculosis Vaccine Trial

Aeras and the Oxford-Emergent Tuberculosis Consortium have announced the start of a Phase IIb proof-of-concept efficacy trial of a new TB vaccine.

Aeras, a TB vaccines and biologics development organization, and the Oxford-Emergent Tuberculosis Consortium (OETC), a joint venture of Emergent BioSolutions and the University of Oxford, have commenced a Phase IIb proof-of-concept efficacy trial of an investigational tuberculosis vaccine for HIV patients.

The MVA85A vaccine candidate developed by OETC and Aeras is intended to boost the response of T-cells already stimulated by the BCG vaccine.

The trial will involve 1,400 adults aged 18-50, and will be conducted at research sites in Senegal and South Africa with primary funding support from the European and Developing Countries Clinical Trials Partnership.

The